Staphylococcus aureus, methicillin sensitive
Antibiotic |
% Susceptible |
Antibiotic |
% Susceptible |
|
| Ampicillin | - |
Imipenem | + |
|
| Azithromycin | 51 |
Levofloxacin | 92 |
|
| Aztreonam | - |
Meropenem | + |
|
| Cefazolin | 100 |
Moxifloxacin | 97
|
|
| Cefepime | + |
Nitrofurantoin | &
|
|
| Ceftazidime | +/- |
Oxacillin/Naf | 100 |
|
| Ceftriaxone | 95 |
Penicillin | 6 |
|
| Cefuroxime | + |
Piperacillin | -
|
|
| Ciprofloxacin | 85 |
Piperacillin/tazo | + |
|
| Clarithromycin | + |
Ticarcillin/Clav | + |
|
| Clindamycin | 78 |
Tobramycin | + |
|
| Doxycycline | 97 |
TMP/SMX | 100 |
|
| Erythromycin | 68 |
Unasyn/Aug | 99 |
|
| Gentamicin | + |
Vancomycin | 100 |
|
Comments: Fluoroquinolone use as first line agents against Staph aureus is discouraged.
Numeric data represent local susceptibility data.
(+) = usually effective or >60% susceptible; (+/-) = clinical trials lacking or 30-60% susceptible; (-) = not effective clinically or <30% susceptible - Adapted with permission from The Sanford Guide to Antimicrobial Therapy 2007
(*) Local (non-Sanford Guide) opinion
(S) = synergistic with penicillin/ampicillin;
(&) nitrofurantoin only useful for lower tract urinary tract infections
(+) = usually effective or >60% susceptible; (+/-) = clinical trials lacking or 30-60% susceptible; (-) = not effective clinically or <30% susceptible - Adapted with permission from The Sanford Guide to Antimicrobial Therapy 2007
(*) Local (non-Sanford Guide) opinion
(S) = synergistic with penicillin/ampicillin;
(&) nitrofurantoin only useful for lower tract urinary tract infections
